Oslo, Norway, November 10, 2021 - Vaccibody AS, a clinical-stage
biopharmaceutical company dedicated to the discovery and development of vaccines
and novel immunotherapies, announced today that its Chief Executive Officer,
Michael Engsig and Chief Innovation and Strategy Officer, Agnete Fredriksen,
will present at Jefferies London Healthcare Conference on November 16, 2021 at
9.40 am CET and be available for 1:1 investor meetings.
The presentation may be viewed here:
Vaccibody, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies for the
treatment cancer and infectious diseases. Vaccibody's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment
of human papilloma virus 16 induced malignancies which is in Phase 2 for the
treatment of cervical cancer